As of September 30, 2026, Black Diamond Therapeutics, Inc. carries a market capitalization of 108.33M, placing it among publicly traded companies globally. Its enterprise value stands at 22.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 108.33M |
| Enterprise Value | 22.33M |
Black Diamond Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 24, 2027.
| Earnings Date | 3/24/2027 |
As of September 30, 2026, Black Diamond Therapeutics, Inc. has 57.47M shares outstanding.
| Shares Outstanding | 57.47M |
These figures are as of September 30, 2026.
| PB Ratio | 1.23 |
| P/TBV Ratio | 1.23 |
| P/FCF Ratio | -3.24 |
| P/OCF Ratio | -3.24 |
As of September 30, 2026, Black Diamond Therapeutics, Inc. maintains a current ratio of 6.92, meaning it holds 6.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.92 |
| Quick Ratio | 6.62 |
| Debt / Equity | 18.21 |
| Debt / EBITDA | -0.30 |
Over the twelve months ended September 30, 2026, Black Diamond Therapeutics, Inc. posted a negative return on equity (ROE) of -41.14, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -32.25, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 21.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -41.14 |
| Return on Assets (ROA) | -32.25 |
| Employee Count | 21.00 |
As of the close on November 16, 2026, Black Diamond Therapeutics, Inc.'s stock has declined approximately 61.85% over the past 52 weeks. The 50-day moving average sits at 1.84, while the 200-day moving average is 2.14.
| 52-Week Price Change | -61.85% |
| 50-Day Moving Average | 1.84 |
| 200-Day Moving Average | 2.14 |
Over the twelve months ended September 30, 2026, Black Diamond Therapeutics, Inc. generated - - in revenue and converted that into -44.07M in net income, yielding earnings per share of -0.77. EBITDA reached -52.90M, while operating income came in at -45.70M.
| Operating Income | -45.70M |
| Pretax Income | -44.07M |
| Net Income | -44.07M |
| EBITDA | -52.90M |
| EBIT | -53.05M |
| Earnings Per Share (EPS) | -0.77 |
As of September 30, 2026, Black Diamond Therapeutics, Inc. holds 102.03M in cash and equivalents against 16.04M in total debt, resulting in a net debt position of -15.08M. Total book value stands at 88.08M, with working capital of 91.14M providing operational flexibility.
| Cash & Cash Equivalents | 102.03M |
| Total Debt | 16.04M |
| Net Debt | -15.08M |
| Equity (Book Value) | 88.08M |
| Book Value Per Share | 1.53 |
| Working Capital | 91.14M |
Black Diamond Therapeutics, Inc. produced -33.32M in operating cash flow over the twelve months ended September 30, 2026.
| Operating Cash Flow | -33.32M |
| Free Cash Flow | -33.32M |
| FCF Per Share | -0.58 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -30.86: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.14, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Black Diamond Therapeutics, Inc. shareholders.
| Shareholder Yield | 0.14 |
| FCF Yield | -30.86 |
As of September 30, 2026, Black Diamond Therapeutics, Inc. has an Altman Z-Score of -3.97, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.97 |